Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
GHRP-2 vs Ipamorelin
An educational, source-based comparison of GHRP-2 and Ipamorelin — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic hexapeptide that activates the ghrelin/GHS-R1a receptor, stimulating endogenous GH release. Compared to Ipamorelin, GHRP-2 produces a stronger GH pulse but also modestly elevates cortisol, prolactin, and appetite.
- GH release in adult GH deficiency
- Appetite stimulation in cachexia models
- Diagnostic GH stimulation testing
- • Not FDA-approved.
- • Less receptor-selective than Ipamorelin; expect appetite and cortisol effects.
- • Prohibited by WADA.
A selective ghrelin/GHS-R1a receptor agonist that stimulates GH release with minimal effect on cortisol, prolactin, or appetite — distinguishing it from older secretagogues like GHRP-6.
- Endogenous GH release without cortisol elevation
- Sleep quality and recovery markers
- Lean tissue retention in catabolic states
- • Generally well tolerated in research; long-term human safety data are limited.
- • Not FDA-approved.
- • Use in sport is prohibited (WADA).
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| GHRP-2 | GHRP-2 stimulates GH release in healthy and GH-deficient adults | Journal of Clinical Endocrinology & Metabolism | 1997 | Established robust GH response after subcutaneous administration. |
| Ipamorelin | Ipamorelin, the first selective growth hormone secretagogue | European Journal of Endocrinology | 1998 | Characterized selectivity for GH release without affecting ACTH, cortisol, or prolactin. |
Side-effect & safety grid
- Not FDA-approved.
- Less receptor-selective than Ipamorelin; expect appetite and cortisol effects.
- Prohibited by WADA.
- Generally well tolerated in research; long-term human safety data are limited.
- Not FDA-approved.
- Use in sport is prohibited (WADA).
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
GHRP-2 vs Ipamorelin — Key differences
- Class: GHRP-2 is classified as Growth Hormone Axis, while Ipamorelin is Growth Hormone Axis.
- Primary research focus: GHRP-2 — gh release in adult gh deficiency; Ipamorelin — endogenous gh release without cortisol elevation.
- Tag: Growth hormone vs Recovery · Sleep.